Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.14% | 4.15% | 51.79% | 8.25% | 23.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.14% | 4.15% | 51.79% | 8.25% | 23.63% |
| Cost of Revenue | -3.40% | -7.52% | -31.60% | -7.35% | -11.80% |
| Gross Profit | -13.84% | 10.98% | 135.10% | 19.81% | 58.58% |
| SG&A Expenses | 67.63% | 64.20% | 54.29% | 43.38% | -19.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.66% | 41.96% | 14.87% | 33.49% | -20.00% |
| Operating Income | -247.20% | -248.76% | 101.31% | -94.51% | 63.49% |
| Income Before Tax | -113.10% | -429.15% | 50.16% | -259.00% | 35.15% |
| Income Tax Expenses | -113.86% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.27% | -465.55% | 52.61% | -259.00% | 34.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.27% | -465.55% | 52.61% | -259.00% | 34.33% |
| EBIT | -247.20% | -248.76% | 101.31% | -94.51% | 63.49% |
| EBITDA | -292.42% | -284.81% | 106.63% | -104.44% | 66.33% |
| EPS Basic | -54.93% | -301.27% | 70.10% | -220.21% | 46.85% |
| Normalized Basic EPS | -67.64% | -276.19% | 51.33% | -12,000.00% | 54.26% |
| EPS Diluted | -54.93% | -312.70% | 70.10% | -258.45% | 47.22% |
| Normalized Diluted EPS | -67.64% | -276.19% | 51.33% | -15,457.14% | 54.26% |
| Average Basic Shares Outstanding | 35.71% | 40.82% | 58.52% | 32.32% | 23.55% |
| Average Diluted Shares Outstanding | 35.71% | 40.82% | 58.52% | -0.24% | 23.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |